 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...345678910111213...208209» |
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New trial: An Exploratory, Single-Arm Study of Adebrelimab and Famitinib for Locally Advanced Head and Neck Squamous Cell Carcinoma (EUDRACT) - Apr 23, 2026
P=N/A, N=30, , Sponsor: Shandong Second Provincial General Hospital; Shandong Second Provincial General Hospital
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P2 trial: A Multicenter, Open-Label, Randomized, Phase II Clinical Trial of Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer (EUDRACT) - Apr 23, 2026
P2, N=108, , Sponsor: ChongQing university cancer hospital; ChongQing university cancer hospital
- | Cypsedo (cipepofol) / Haisco, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: The median effective dose of Tegileridine when combined with ciprofol for hysteroscopy (EUDRACT) - Apr 23, 2026
P=N/A, N=40, Recruiting, Sponsor: The People
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: A Randomized, Open-Label Trial of Trastuzumab Combined with Pyrotinib and Taxanes (THPy) versus Trastuzumab Combined with Pertuzumab and Taxanes (THP) as First?Line Treatment for Advanced HER2?Positive Breast Cancer (EUDRACT) - Apr 23, 2026
P4, N=568, Recruiting, Sponsor: Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital
Not yet recruiting --> Recruiting
- ||| SHR-4394 / Jiangsu Hengrui Pharma
Enrollment open: A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer (clinicaltrials.gov) - Apr 21, 2026
P1/2, N=100, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Enrollment open: HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov) - Apr 21, 2026
P=N/A, N=150, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Enrollment open: HCC-SIGHT: A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 21, 2026
P2, N=350, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Combined therapy using gemcitabine and cisplatin chemotherapy, lenvatinib, and adebrelimab for patients with advanced and unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_8024;
Not yet recruiting --> Recruiting Funding: National Natural Science Foundation of China Clinical Trial Registration Number: 06298968 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma: Updated results. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_8006;
P2
82570716), Major Program of the Ministry of Science and Technology of the People's Republic of China (No. 2025ZD01906000) Clinical Trial Registration Number: ChiCTR2300078869 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Hepatic artery infusion chemotherapy plus adebrelimab and bevacizumab as first-line treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_8005;
P=N/A
2025ZD01906000) Clinical Trial Registration Number: ChiCTR2300078869 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funding: National Health Commission Medical and Health Science and Technology Development Research Center Clinical Trial Registration Number: ChiCTR2400094431 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Transarterial embolization plus hepatic arterial infusion chemotherapy combined with rivoceranib and camrelizumab for initially unresectable hepatocellular carcinoma with high tumor burden: A single-arm, prospective, multicenter study. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_7908;
P2
Funding: National Health Commission Medical and Health Science and Technology Development Research Center Clinical Trial Registration Number: ChiCTR2400094431 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funding: Joint Funds for the Innovation of Science and Technology, Fujian Province Clinical Trial Registration Number: NCT06363825 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- garetatug rezetecan (SHR-A1904) / EMD Serono
A global phase 1/2a trial of SHR-A1904, a CLDN18.2-targeting ADC, in advanced solid tumors expressing CLDN18.2. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_7904;
P1/2
Funding: Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT05277168 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics
Effectiveness and safety of transarterial chemoembolization combined with apatinib in hepatocellular carcinoma: A systematic review and proportional meta-analysis. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_7029;
Clinical Trial Registration Number: NCT05277168 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, Stivarga (regorafenib) / Bayer
Regorafenib vs. apatinib: An indirect treatment comparison in the treatment of advanced gastric cancer. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6274;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Pyrotinib versus pertuzumab plus trastuzumab and taxane as first-line therapy for HER2-positive advanced breast cancer: A retrospective cohort study using propensity score overlap weighting. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6132;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
PD-1 inhibition with camrelizumab in cervical cancer: A systematic review and meta-analysis. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_6012;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Tevimbra (tislelizumab-jsgr) / BeOne Medicines, AiTan (rivoceranib) / Elevar Therapeutics
Efficacy and safety of tislelizumab and apatinib combined with hepatic arterial infusion chemotherapy for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 study. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_5288;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab combined with concurrent chemoradiotherapy versus chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A retrospective cohort study in central China. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4865;
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Apatinib combined with adebrelimab and GEMOX regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A multicenter, open-label, single-arm, phase II trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4583;
P2
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06925516 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
A phase Ib/II clinical study of adebrelimab in combination with capecitabine and oxaliplatin for previously untreated patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4579;
P1/2
Clinical Trial Registration Number: NCT06925516 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06776770 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Neoadjuvant systemic chemotherapy combined with camrelizumab (CAM) and apatinib (APA) for BCLC stage A/B hepatocellular carcinoma (HCC) beyond Milan criteria: An interim analysis of a phase 2 trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4571;
P2
Clinical Trial Registration Number: NCT06776770 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06607107 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Comparable clinical efficacy of pyrotinib in trastuzumab-naive and trastuzumab-exposed HER2-positive advanced breast cancer patients: A prospective, multicenter, real-world study. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4565;
P=N/A
Clinical Trial Registration Number: NCT06607107 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06495541 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Liposomal irinotecan combined with oxaliplatin, 5-fluorouracil/leucovorin with or without camrelizumab as preoperative chemotherapy for borderline resectable pancreatic cancer: Preliminary results of a single-center phase II exploratory study. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4555;
P2
Clinical Trial Registration Number: NCT06495541 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06345300 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Neoadjuvant camrelizumab with chemotherapy (NACI) in PD-L1-negative locally advanced cervical cancer: An open-label, multi-center, single-arm, phase 2 trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4553;
P2
Clinical Trial Registration Number: NCT06345300 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06288360 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
NEO-ERA-01(CLEAP2507): A multi-center, single-arm, phase II study with neoadjuvant therapy of HAIC (GEMOX) combined with adebrelimab and lenvatinib for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4551;
P2
Clinical Trial Registration Number: NCT06288360 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06208462 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Efficacy and safety of hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in patients with gynecologic malignancies: A single-arm phase 2 trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4546;
P2
Clinical Trial Registration Number: NCT06208462 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06099925 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Aqupla (nedaplatin) / Simcere, Fruzaqla (fruquintinib) / Takeda, AiRuiKa (camrelizumab) / Elevar Therapeutics
Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4542;
P1/2
Clinical Trial Registration Number: NCT06099925 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06010212 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab combined with capecitabine as maintenance therapy for metastatic nasopharyngeal carcinoma: A phase II single-arm clinical trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4496;
P2
Clinical Trial Registration Number: NCT06010212 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2500111883 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Neoadjuvant pyrotinib plus trastuzumab combined with chemotherapy for HER2+/HR+ early breast cancer: A multicenter phase 2 trail. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4491;
P2
Clinical Trial Registration Number: ChiCTR2500111883 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2500102478 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Real-world study of adebrelimab for immune resumption after immune-related adverse events (irAEs). () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4490;
P=N/A
Clinical Trial Registration Number: ChiCTR2500102478 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2500101774 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Focus V (anlotinib) / Advenchen, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab in combination with anlotinib and chemotherapy as neoadjuvant therapy for resectable stage II-III non () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4488;
P2
Clinical Trial Registration Number: ChiCTR2500101774 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2500100571 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab combined with concurrent chemoradiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm clinical trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4480;
P4
Clinical Trial Registration Number: ChiCTR2500100571 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2400084445 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
A phase II, single-arm trial of adebrelimab plus nab-paclitaxel and carboplatin as first-line therapy for advanced thymic carcinoma: Interim efficacy and safety results. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4475;
P2
Clinical Trial Registration Number: ChiCTR2400084445 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2300072705 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Dual HER2-targeted therapy with pyrotinib plus inetetamab and adebrelimab in previously treated HER2-amplified metastatic colorectal cancer: A prospective, single-arm, phase II clinical trial. () - Apr 21, 2026 - Abstract #ASCO2026ASCO_4463;
P=N/A
Clinical Trial Registration Number: ChiCTR2300072705 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2000038709 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Neoadjuvant dalpiciclib combined with letrozole and dual HER2 blockade in HR+/HER2+ breast cancer: First-stage results of the HELEN HER2 017 trial. (Hall A - Posters and Exhibits; Poster Bd #: 168) - Apr 21, 2026 - Abstract #ASCO2026ASCO_4254;
P2
Clinical Trial Registration Number: ChiCTR2000038709 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06276868 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- HRS-8080 / Jiangsu Hengrui Pharma
HRS-8080, an oral selective estrogen receptor degrader (SERD), in ER+/HER2? advanced breast cancer (aBC) with ESR1 mutations (ESR1m): Results from a first-in-human phase 1 trial. (Hall A - Posters and Exhibits; Poster Bd #: 183) - Apr 21, 2026 - Abstract #ASCO2026ASCO_4180;
P1
Clinical Trial Registration Number: NCT06276868 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT05189717 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, utidelone IV (UTD1) / Beijing Biostar Technologies
Efficacy and safety results of a prospective phase II study (IPUtrial) of inetetamab and pyrotinib in combination with utidelone for first- or second-line treatment of HER2-positive metastatic breast cancer. (Hall A - Posters and Exhibits; Poster Bd #: 164) - Apr 21, 2026 - Abstract #ASCO2026ASCO_4162;
Funded by Beijing Biostar Pharmaceuticals Co., Ltd. The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Neoadjuvant treatment of recurrent high-grade gliomas with camrelizumab in combination with apatinib: A prospective phase II clinical study. (Hall A - Posters and Exhibits; Poster Bd #: 426) - Apr 21, 2026 - Abstract #ASCO2026ASCO_4040;
P2
The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Natural Science Foundation of China Clinical Trial Registration Number: NCT04588987 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics
Low-dose apatinib combination with first-line chemotherapy rechallenge in advanced osteosarcoma: A single-center ambispective cohort study. (Hall A - Posters and Exhibits; Poster Bd #: 319) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3939;
Funded by National Natural Science Foundation of China Clinical Trial Registration Number: NCT04588987 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pyrotinib plus nab-paclitaxel as adjuvant therapy for patients with N0/N1mi, HER2-positive early-stage breast cancer: 3-year iDFS results of the phase II PHAEDRA trial. (Hall A - Posters and Exhibits; Poster Bd #: 18) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3913;
P2
Funded by Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by General Project of the 2025 Annual Beijing Municipal Education Science , National High Level Hospital Clinical Research Funding, Chronic Disease Management Research Project of National Health Commission Capacity Building and Continuing Education Center Clinical Trial Registration Number: NCT 04659499 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
A molecular subtype (Hall A - Posters and Exhibits; Poster Bd #: 132b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3892;
P2
Funded by General Project of the 2025 Annual Beijing Municipal Education Science , National High Level Hospital Clinical Research Funding, Chronic Disease Management Research Project of National Health Commission Capacity Building and Continuing Education Center Clinical Trial Registration Number: NCT 04659499 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT07307287 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche
Early results of neoadjuvant therapy with pyrotinib, subcutaneous trastuzumab, and capecitabine for HER2-positive early breast cancer from a prospective, single-arm, multicenter trial. (Hall A - Posters and Exhibits; Poster Bd #: 91) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3801;
P2
Clinical Trial Registration Number: NCT07307287 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT06483386 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
Neoadjuvant pyrotinib vs pertuzumab therapy for HER2-positive early breast cancer: The HELEN HER-013 randomized clinical trial. (Hall D2) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3614;
P2
Clinical Trial Registration Number: NCT06483386 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: NCT05918328 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial. (Hall B1) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3557;
P3
Clinical Trial Registration Number: NCT05918328 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT05320692 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
Updated efficacy of dalpiciclib and nonsteroidal aromatase inhibitors (NSAIs) in estrogen receptor (Hall A - Posters and Exhibits; Poster Bd #: 225) - Apr 21, 2026 - Abstract #ASCO2026ASCO_3450;
P2
Funded by Jiangsu Hengrui Pharmaceuticals Clinical Trial Registration Number: NCT05320692 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2000040597 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab combined with liposomal doxorubicin and dacarbazine as first-line therapy for advanced, recurrent, and metastatic undifferentiated pleomorphic sarcoma: A phase II study. (S504) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2905;
P4
Clinical Trial Registration Number: ChiCTR2000040597 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Clinical Trial Registration Number: ChiCTR2100049974 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Avastin (bevacizumab) / Roche, Airuituo (bevacizumab biosimilar) / Jiangsu Hengrui Pharma
Impact of bevacizumab on the efficacy of antibody (Hall D1) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2869;
P2
Clinical Trial Registration Number: ChiCTR2100049974 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by National Natural Science Foundation of China Clinical Trial Registration Number: NCT05749588 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
SHR-1701 combined with fuzuloparib and chemotherapy as first-line therapy for advanced lung squamous cell carcinoma: Efficacy and safety results from a phase II study. (Hall A - Posters and Exhibits; Poster Bd #: 359) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2785;
P2
Funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT04937972 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- SHR-A2102 / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
SHR-A2102 in combination with adebrelimab as first-line treatment in patients with locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC): Results from a phase 1b/2 study. (Hall A - Posters and Exhibits; Poster Bd #: 317) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2766;
P1/2
Funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Clinical Trial Registration Number: NCT06512051 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.
- Keytruda (pembrolizumab) / Merck (MSD), plinabulin (BPI 2358) / BeyondSpring
A phase 2 study of plinabulin (Plin)/docetaxel (Doc) plus pembrolizumab (Pemb) in metastatic NSCLC (mNSCLC) after acquired resistance (AR) to anti (Hall A - Posters and Exhibits; Poster Bd #: 357) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2671;
P2
Clinical Trial Registration Number: NCT06512051 The full, final text of this abstract will be available on May 21 at 05:00 PM EST. Funded by BeyondSpring Pharmaceuticals, Inc Clinical Trial Registration Number: NCT05599789 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.